AlphAIAlphAI — Financial news for AI agents
tradingview.comSEP 171 min read

BTIG reiterates Buy rating on Neuronetics, $6 price target

BTIG maintained a Buy rating on Neuronetics with a $6 price target, suggesting 117.4% upside from the last close. The company reported 17% revenue growth and introduced a new go-to-market strategy, aiming to expand its customer base and improve operational efficiency.

Original reporting
tradingview.com
Published Sep 17, 2026, 4:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 17, 2026, 5:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
BTIG reiterates Buy rating on Neuronetics, $6 price target — source image
Source · tradingview.com
Decision brief

The 30-second read

Med
01

Why it matters

The analyst note highlights operational improvements and a new leasing model as growth drivers.

02

Market read

The rating change could attract new buying interest and support price gains.

03

What to watch

Potential reimbursement challenges and execution risk of the new go‑to‑market model.

Relevance 7/10Novelty 6/10Timing: today

Background

Neuronetics reported 17% YoY revenue growth and 50% clinic occupancy, prompting the rating upgrade.

Market effects

Sector

Positive signal for the neurostimulation/medical device sector.

Regional

Limited to U.S. markets where Neuronetics trades.

Global

Minimal global impact beyond sector peers.

Counterpoint

What could challenge this read

The target may be overly optimistic given competitive pressures.

Key entities

  • company
    Neuronetics

    Medical device maker focused on neurostimulation.

  • analyst
    BTIG

    Equity research firm issuing the Buy rating.

Read at source← All news

Related articles

AUG 18
$STIMMedAI 8/10

Neuronetics (STIM) Q2 2026 Earnings Call Transcript

Neuronetics (STIM) reported Q2 2026 revenue of $41.6M, up 9.1% YoY. Greenbrook revenue grew 16.8% YoY, while NeuroStar revenue fell 2.7% YoY. Net loss narrowed to $3.4M. Full-year revenue guidance was set at $160M-$164M, with gross margin guidance raised to 48%-50%. The company expanded NeuroStar acquisition options and integrated AI into operations. Management highlighted growth opportunities in psychedelic-based therapies and strategic collaborations.

fool.com6 min
AUG 13
Med

Neuronetics, Inc. Q2 2026 Earnings Call Summary

Neuronetics reported Q2 2026 progress on its NeuroStar commercial shift to hybrid capital purchase and lease options, with 17% YoY growth at Greenbrook clinics and a 10% utilization increase in active NeuroStar accounts. Management expects choppier H2 2026 revenue, raised full-year gross margin guidance to 48%-50%, and cut operating expense guidance by $5M.

yahoo.com5 min
AUG 13
$STIMMedAI 8/10

Neuronetics Q2 Earnings Call Highlights

Neuronetics (NASDAQ:STIM) reported Q2 Worldwide NeuroStar revenue of $14.7M, down 2.7% YoY, with capital revenue up and treatment-session revenue down. The company expanded NeuroStar purchase and leasing options, expects no further material inventory reduction in H2, and plans to report NeuroStar as a single revenue line. Gross margin rose to 61.1% and 2026 guidance was narrowed to $160M-$164M.

yahoo.com6 min
AUG 11
$STIMHighAI 8/10

Why is Neuronetics stock surging today?

Neuronetics shares rose about 24% in pre-open after the company reported Q2 2026 results that beat Wall Street on revenue and EPS. Revenue was $41.6M (+9.1% YoY). Net loss narrowed to $3.4M, or -$0.05/share, versus -$10.1M and -$0.15/share a year earlier. Greenbrook revenue grew to $26.9M (+16.8%).

investing.com3 min